A subcutaneous infusion of Remodulin (treprostinil) was an effective and tolerable treatment against severe pulmonary hypertension associated with chronic kidney disease in a patient on hemodialysis, according to a case report. The case study “Subcutaneous treprostinil was effective and tolerable in a patient with severe pulmonary hypertension associated with…
News
Early renal denervation (RDN) treatment improved pulmonary arterial hypertension (PAH) in a rat model, a new study from China showed. The study titled, “Effects of renal denervation on monocrotaline induced pulmonary remodeling,” was published in the journal Oncotarget. Despite the progress achieved with oral therapies over the last two decades, the prognosis…
Scientists have long known that people with scleroderma are at increased risk of developing pulmonary arterial hypertension. But many with scleroderma whom doctors suspect of having PAH are not receiving optimal screening for the respiratory condition, a study concludes. Nor are enough scleroderma patients suspected of having pulmonary hypertension being referred for tests that…
MannKind Corporation, which is developing the pulmonary arterial hypertension (PAH) therapy Treprostinil Technosphere, has retained the biopharmaceutical financing specialist Locust Walk to help it raise capital for Treprostinil and other projects. Locust Walk lines up investors and strategic partners for companies like MannKind, which also wants to use its Technosphere technology to develop…
Researchers implanted a long-term, intravenous therapy-delivery system consisting of internal pumps and catheters in 60 pulmonary arterial hypertension (PAH) patients, according to a clinical trial. The IV infusion system, developed by Medtronic, delivers Remodulin (treprostinil). The research team said the system should be easier to use than current therapy-delivery methods.
Patients who undergo splenectomy, or surgery to remove the spleen, increase their risk of pulmonary hypertension (PH), myocardial infarction and stroke. That’s the conclusion of a study, “Risk of cardiovascular events and pulmonary hypertension following splenectomy – a Danish population-based cohort study from 1996-2012,” that appeared in the journal Haematologica.
The average systemic sclerosis (SSc) patient burdened with pulmonary arterial hypertension (PAH) lives only four years after diagnosis, finds an Australian study, “Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension,” that appeared in the journal Arthritis Research & Therapy. PAH is a serious…
Whether a pulmonary arterial hypertension patient has scleroderma has no bearing on the outcome of their PAH after they receive a lung transplant, a study reports. Scleroderma, also known as systemic sclerosis, is a chronic autoimmune disease caused by abnormal production of connective tissue. It primarily affects the skin…
People with chronic thromboembolic pulmonary hypertension (CTEPH) are more likely to have a depressive temperament, finds a Japanese study, “Depressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension” that appeared in the Circulation Journal. CTEPH is a progressive disease characterized by increasing pulmonary vascular resistance. Although the underlying…
A live, online mini-concert starring Chloe Temtchine has drawn thousands of viewers while raising awareness about pulmonary hypertension (PH), a progressive, life-threatening disease. The Facebook Live concert, presented recently by the Pulmonary Hypertension Association (PHA), attracted 1,500 live attendees and served as the finale for PHA’s World PH Day, the culmination…
Reviva Pharmaceuticals has obtained $4.8 million in financing to keep developing its treatments for pulmonary arterial hypertension (PAH) and other diseases. The financing, in the form of a loan that can be converted to stock, will help Reviva continue preparing for new clinical trials of its lead therapy, RP5063, Dr. Laxminarayan Bhat said…
Compounds that increase the amount of blood flowing through heart vessels can benefit people with pulmonary hypertension (PH) and chronic left heart disease who have decreased blood-pumping ability, according to an analysis of several studies. The compounds are phosphodiesterase-5 (PDE5) inhibitors such as Revatio (sildenafil). They prevent an enzyme called…
